Work

Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.

Year: 2017

Type: article

Abstract: , in MCA-exposed SVHUC-AR cells. Thus, enzalutamide, flutamide, and bicalutamide were found to similarly prevent neoplastic transformation of urothelial cells. These findings offer a potential chemopreventive approach for urothelial tumors using AR antagonists.

Source: PubMed

Authors: Takashi Kawahara, Satoshi Inoue, Eiji Kashiwagi, Jinbo Chen, Hiroki Ide, Taichi Mizushima, Yi Li, Yichun Zheng, Hiroshi Miyamoto

Institutions: Johns Hopkins University, Johns Hopkins Medicine, University of Rochester Medicine, University of Rochester

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3021117261

FWCI: 4.464

Cites: 36

Cited by: 30

Related to: 10